Viatris Corp - Multiplikator Forward P/S VTRS

Viatris Inc. is expanding its portfolio through biotech partnerships and global licensing. Balance sheet deleveraging and the launch of complex biosimilars are driving growth. The P/S forward valuation history on the GURU.Markets chart clearly demonstrates market expectations, where the 1.60 level captures recent values. Stable cash flow from core brands supports the company while new growth catalysts emerge.

VTRS (viatris.com) riwayat Rasio rega marang prakiraan pendapatan saka 04.07.2022 nganti 15.11.2026

Rincian metrik lan analitis perusahaan Viatris (VTRS)

- rega pasar lan target rega analis:

Bagan rega Viatris Inc.|VTRS - Prakiraan gabungan firma investasi

- rincian nilai pasar emiten:

Kapitalisasi pasar Viatris Inc.|VTRS - Nilai Perusahaan Nalika Diakuisisi Penuh

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham Viatris|VTRS - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku viatris.com|VTRS - Gunggung Aset Perusahaan

- rincian utang lan likuiditas:

Total Utang marang Modal Viatris Inc.|VTRS - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Viatris Inc.|VTRS - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Viatris Inc|VTRS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Viatris|Likuiditas cepet viatris.com

- indikator pendapatan resik lan kelipatan nilai:

VTRS - Asil keuangan resik|Bathi mangsa ngarep Viatris Inc.|VTRS - Nilai perusahaan marang bathi resik|Pangali Forward P/E viatris.com|VTRS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Viatris Corp|VTRS - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Viatris|VTRS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan viatris.com|VTRS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Viatris Inc.

- indikator pendapatan dodolan lan penghasilan bisnis:

VTRS - Pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Viatris|VTRS - Kapitalisasi marang volume dodolan|Rasio rega marang prakiraan pendapatan Viatris Inc|VTRS - Dinamika pendapatan YoY sajrone rolas wulan kepungkur

Analisis umum perusahaan:VTRS (Viatris Corp)

Viatris Inc. (VTRS) expansion into emerging markets and complex therapeutic niches is directly reflected in the forward P/S history. This indicator compares the company's current market value with expected annual revenue, transforming analyst forecasts into a daily trend. A declining multiple amid stable sales may signal that assets are undervalued against the backdrop of a maturing branded generics market.

Pesaing wigati

Multiplikator Forward P/S LLY (Lilly)|ABBV: Kapitalisasi marang prakiraan pendapatan|AstraZeneca Corp. - Multiplikator Forward P/S|NVS (novartis.com) - Kapitalisasi marang prakiraan pendapatan|MRK: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Novo Nordisk Inc. (NVO)|Rasio rega marang prakiraan pendapatan Amgen Inc|Pfizer Inc. (PFE) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Sanofi SA (SNY)|Rasio kapitalisasi marang dodolan sing dikarepake Bristol Myers Squibb|Rasio rega marang prakiraan pendapatan GlaxoSmithKline plc GSK|TAK: Kapitalisasi marang prakiraan pendapatan|TEVA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Dr. Reddy's Lab|Roivant Sciences (ROIV) - Rasio rega marang prakiraan pendapatan|Zai Lab Limited (ZLAB) - Multiplikator Forward P/S|BHC (Bausch Health) - Multiplikator Forward P/S|COSM: Rega forward marang dodolan